Abstract Purpose:[177Lu] Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be
applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA
expression. In this prospective study (NCT03828838), we analyzed toxicity, radiation doses,
and treatment effect of 177Lu-PSMA in pateints with low-volume mHSPC. Patients and
Methods: Ten progressive patients with mHSPC following local treatment, with a maximum …

Ziel/Aim±30% of prostate cancer (PC) patients present with disease recurrence after radical
surgery or radiotherapy. Lutetium-177-PSMA-617 (Lu-PSMA) is a promising treatment for
castration-resistant PC. Based on the mode of action, patients in the hormone sensitive (HS)
stage could potentially benefit too. We aimed to investigate the tolerability, dosimetry, and
treatment response of Lu-PSMA in these early stage patients who presented with disease
recurrence and had high expression on PSMA-PET. Methodik/Methods In this ongoing …